Can Diabetes Cause Uterine Cancer? ICMR sheds light Anshika Mishra29 Jun 2024 8:30 AM ISTDiabetes is a global health crisis, with millions being diagnosed each year. While complications such as heart disease, kidney disease, and nerve...
AstraZeneca Imfinzi plus chemotherapy gets USFDA nod for mismatch repair deficient advanced or recurrent endometrial cancer Ruchika Sharma17 Jun 2024 11:30 AM ISTCambridge: AstraZeneca has announced that Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy has...
Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint: Merck Ruchika Sharma11 May 2024 12:41 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYNOTE-B21 trial evaluating KEYTRUDA,...
Why is India witnessing a rise in Uterus Cancer in Older Women? - Dr Prathima Reddy Dr Prathima Reddy30 April 2024 11:42 AM ISTUterine cancer, primarily affecting postmenopausal women, has seen a concerning uptick in incidence rates in recent times. This surge in cases is...
GSK application for expanded indication of Jemperli plus chemotherapy accepted by USFDA for priority review Ruchika Sharma25 April 2024 12:40 PM ISTLondon: GSK plc has announced the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for...
Merck application for Keytruda plus chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma accepted by USFDA for priority review Ruchika Sharma22 Feb 2024 12:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has accepted for...
GSK Gets CDSCO Panel Nod to study safety of anti-cancer drug Dostarlimab Dr. Divya Colin23 Dec 2023 6:00 PM ISTNew Delhi: Citing that the total number of evaluable patients in the study should be a minimum of 30, the Subject Expert Committee (SEC) functional...
Jemperli plus Zejula combo significantly improved progression-free survival in primary advanced or recurrent endometrial cancer: GSK Ruchika Sharma20 Dec 2023 2:30 PM ISTLondon: GSK plc has announced positive headline results from a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial...
GSK gets European Commission marketing authorisation for Jemperli, chemotherapy combo for endometrial cancer Ruchika Sharma13 Dec 2023 3:30 PM ISTLondon: GSK plc has announced the European Commission (EC) has granted marketing authorisation for Jemperli (dostarlimab) in combination with...
Night Shift Work Not Fully Linked to Endometrial Cancer in Postmenopausal Women Jacinthlyn Sylvia7 Nov 2023 9:00 PM ISTA recent study by the Epidemiology of Endometrial Cancer Consortium (E2C2) suggests that there is limited evidence to support night shift work and...
Phase III trial of Jemperli plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer: GSK Ruchika Sharma31 Oct 2023 11:35 AM ISTLondon: GSK plc has announced positive headline results from a planned analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial...
GSK gets positive EMA Committee opinion recommending approval of Jemperli plus chemotherapy for endometrial cancer Ruchika Sharma19 Oct 2023 2:41 PM ISTUK: GSK plc has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive...
